

Strategic priorities for the OECI

Quality improvement in Cancer Care and Research

The Accreditation and Designation Programme, specifically designed for cancer centres, aims to constantly improve our cancer centres' outcomes for patients and their experience of care. Multidisciplinary working, efficient logistics and complex infrastructure to support patient pathways are needed in order to deliver high quality, patient-centred care to cancer patients. About half of the OECI Members are already included in the A&D Programme, and the present pipeline of applications indicates a steep growth in the programme, extending beyond Europe. Within Europe it comprises more than 50 of the largest centres which have treated more than 1 million patients since their accreditation, and produce more than 12,000 peer reviewed papers annually. The A&D Programme is specifically designed for cancer centres right across Europe, and is unique in certifying both care and research (and having standards certified by the International Society for Quality in Healthcare). The certified centres form an OECI Quality Network. Future impact will include publications of the Programme's experience from twelve years of quality assurance and improvement work, benchmarking, implementation research on networks, and establishing core standards for cancer care across the EU.

Outcomes Cancer Research

The Cancer Outcomes Research Working Group (COR-WG) has been activated in response to the need of collecting prospectively humanistic, clinical and economics outcomes in relevant cohorts of cancer patients, with the final aim to improve cancer outcomes in Europe.

The COR-WG will promote the foundation of a community of researchers, clinicians and other stakeholders to be translated into a flexible, efficient and up-to-date international collaboration centered on (but not limited to) routine medical and health care records, supported by a digital research infrastructure fully compliant with GDPR and local privacy laws.

The expected output is the creation of conditions to favorite the participation of OECI Members to a broad range of high quality research projects that will produce real world evidence to plan better health care interventions.

The Health Economics and Benchmarking activity relates to several policy priorities

The participation to the European Fair Pricing Network and its objectives is aligned with inputs coming from the OECI members. A further priority focuses on comparative data from member countries on real world value of cancer treatments. This activity will be supported by a common "taxonomy" of costs and outcome concepts to be elaborated during a preparation phase under discussion with OECI Members. The policies per country on (cost-)effectiveness, pricing, coverage and indications for targeted combination therapies are also included in the programme of activities carried out by the WG.

The WG membership will be involved in a project on "identifying alternative policies for price setting at market". This launch has been already discussed following a presentation where various scenarios were simulated.

The Working Group is also actively discussing the possible participation to a coveted call under the European Cancer Mission in the preparation phase as part of the incoming Horizon Europe Research Framework Programme. Generating better evidence on value, establishing registries for real word data and monitoring equitable access are the three main topics that could be part of a specific application. These goals may be achieved through a specific interaction with the OECI A&D Programme and the WG on Outcomes Cancer Research.

Patient Involvement and Partnerships

Quality improvement in cancer care and research is a major goal shared by healthcare professionals, researchers and patients. For OECI centres, patients are bringing a different and valuable perspective to the quality improvement process in hospitals, by expressing their special needs and priorities. Today, innovative cancer centres are taking initiatives, involving patients and launching collaborations with local and national patient organisations. The OECI Working Group "Collaboration for Good Practices with Patients" (CGPP) has been set up to solve recurrent challenges shared by cancer centres related to cancer care and research through dedicated, new patient-focused initiatives. The mission is to collect, analyse & disseminate successful, patient-oriented collaborative practices in cancer care and research; a "fact-tank" providing a supportive task force for OECI cancer centres that need methodological tools and expertise to implement new initiatives.

Biobanks and Molecular Pathobiology

The OECI Biobanks and Molecular Pathobiology Working Group, together with some of the major European Cancer Societies/Organisations, contributes to the continuous evolution of molecular oncology to guarantee the reproducibility of analytical methods. The WG develops specific recommendations for standardisation and validation of biomarkers and molecular analysis other than solid and liquid tissues biobanking for a better reproducible use. In order to accelerate the production of new effective protocols of treatment, a study aiming to a practical adoption of N-1 trials is underway. The WG is engaged in some European projects such as Instand-NGS for the clinical standardization of NG sequencing, SPIDIA 4P project for pre-analytical conditions of biological material, and HERCULES project on tumour heterogeneity. The WG collaborates with the OECI Accreditation and Designation Programme for a continuous update of the standards to be adopted. The OECI Pathology Day is the main annual event organised by the WG.

The OECI Board



President
Thierry Philip
Paris, France



Vice-President and Executive Secretary
Giovanni Apolone
Milan, Italy



Treasurer
Manuel Llobart Fuertes
Valencia, Spain



Elected Member
Christian Brandts
Frankfurt, Germany



Elected Member
József Lövey
Budapest, Hungary



Elected Member
Simon Oberst
Cambridge, United Kingdom



Elected Member
Gunnar Sæter
Oslo, Norway



Elected Member
Marien van der Meer
Amsterdam, The Netherlands



OECI Director
Claudio Lombardo
Brussels, Belgium - Genoa, Italy



OECI Central Office
Guy Storme
Brussels, Belgium

Accreditation and Designation Programme



Simon Oberst
Cambridge, United Kingdom

Working Groups



Biobanks and Molecular Pathobiology
Giorgio Stanta
Trieste, Italy



Cancer Outcomes Research
Milena Sant
Milan, Italy



Cancer Economics and Benchmarking
Wim H. van Harten
Amsterdam, The Netherlands



Collaboration for Good Practices with Patients
Dominique de Valeriola
Brussels, Belgium

OECI-EEIG Central Office - c/o Fondation Universitaire - 11, Rue d'Egmont
Phone: +32 2 512 0146, B-1000 Brussels, Belgium

December 2020



**DEVELOPING
THE FUTURE IN
COMPREHENSIVE
CANCER CARE**

www.oeci.eu
oeci@oeci.eu



Organisation
of European
Cancer Institutes

ecancermedicalscience

Official OECI Journal

**ONE MORE REASON
TO JOIN THE OECI
IS CERTIFYING
YOUR QUALITY
IN ONCOLOGY!**

OECI Objectives

The OECI aim is to accelerate the application of multidisciplinary personalised care approaches, to reduce morbidity and to guarantee an equitable access to care to all cancer patients, avoiding the collapse of the National Health Systems all over Europe, and supporting parallel initiatives outside the EU and in other continents.

This goal is being achieved by promoting and enhancing the concept of "comprehensiveness" and "multi-disciplinarity", supporting quality in cancer care and dynamically working in crosscut expertise by involving our Working Groups, our Members and promoting synergies with other cancer Organisations.

The OECI is currently geared towards creating a "network of cancer networks" where primary prevention, screening & early diagnosis, basic, translational & clinical research, collaboration for good practices with patients, biobanks and molecular pathobiology, cancer economics and centralising real-life cancer patient data are included.

The above goal is part of the Presidential proposal of an OECI evolution that may better answer to the need to work on a European Cancer Mission within the incoming Framework Programme "Horizon Europe".

Thierry Philip
OECI President



“The OECI is a non-governmental, non-profit Organisation founded in Vienna in 1979 and remodeled in 2005 into OECI-EEIG, a European Economic Interest Grouping. Today, the OECI regroups 102 Members, which include some of the most prominent European Comprehensive Cancer Centres. Several major cancer centres from the Chile, Colombia, Jordan, Russian Federation, Tanzania, Turkey, Ukraine and Viet Nam are also members of our Organisation in order to benefit from our Accreditation and Designation Programme and to be involved in the activities promoted by the Working Groups.”

OECI NETWORK 2021

Austria

- Comprehensive Cancer Center Vienna, Vienna

Belgium

- ★ Institut Jules Bordet (IJB), Brussels
- ★ Oncologisch Centrum UZBrussel, Brussels
- ★ AZ Groeninge, Kortrijk
- Institut Roi Albert II Cliniques universitaires Saint-Luc, Brussels

Chile

- Instituto Oncológico Fundación Arturo López Pérez (FALP), Santiago

Colombia

- Instituto Nacional de Cancerología – ESE, Bogotá

Croatia

- Klinika za tumore Klinicki bolnički centar Sestre milosrdnice, Zagreb

Czech Republic

- ★ Masarykův onkologický ústav, Brno
- Fakultní nemocnice v Motole, Prague
- Institut biostatistiky a analýz Lékařská fakulta Masarykovy univerzity, Brno

Denmark

- ★ Vejle Sygehus, Patienternes Kræftsygehus en del af Sygehus Lillebælt, Vejle
- Kræftens Bekæmpelse Center for Kræftforskning, Copenhagen

Estonia

- ★ Sihtasutus Tartu Ülikooli Kliinikum, Tartu
- North Estonia Medical Centre, Tallin

Finland

- ★ HUS Syöpäkeskus Helsingin Yliopistollinen Sairaala, Helsinki

- ★ TYKS Syöpäkeskus Turun Yliopistollinen Sairaala, Turku
- ★ TAYS Cancer Centre Tampere University Hospital, Tampere
- ★ KYS Syövänhoitokeskus Kuopion Yliopistollinen Sairaala, Kuopio
- ★ OYS Oulun Yliopistollinen Sairaala, Oulu

France

- ★ Centre Léon Bérard, Lyon
- ★ Institut Curie, Paris
- ★ Institut Paoli – Calmettes, Marseille
- ★ Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse
- ★ Centre François Baclesse, Caen
- ★ APHP-CARPEM Institute, Paris
- ★ Institut de Cancérologie de l'Ouest (ICO), Angers - Saint Herblain
- ★ Association Toulousaine de Oncologie Publique (ATOP), Toulouse

- Gustave Roussy, Villejuif
- Institut de cancérologie Strasbourg Europe ICANS, Strasbourg

- Centre Jean Perrin, Clermont-Ferrand
- Institut du Cancer de Montpellier (ICM), Montpellier
- Institut Godinot, Reims
- Institut de cancérologie des Hospices Civils de Lyon, Lyon

- Assistance Publique - Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université, Paris
- Centre de Lutte Contre le Cancer Georges-François Leclerc, Dijon
- Centre Henri Becquerel, Rouen
- Institut Sainte-Catherine, Avignon

Germany

- Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
- Nationales Zentrum für Tumorerkrankungen Dresden NCT/UCC, Dresden
- Charité Comprehensive Cancer Center, Berlin
- Universitäres Centrum für Tumorerkrankungen (UCT), Frankfurt

Hungary

- ★ Országos Onkológiai Intézet, Budapest
- Országos Korányi TBC és Pulmonológiai Intézet, Budapest

Ireland

- ★ Trinity St. James's Cancer Institute, Dublin
- Beaumont Hospital, Dublin

Italy

- ★ Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano
- ★ IRCCS Ospedale Policlinico San Martino, Genova
- ★ Istituto Europeo di Oncologia, Milano
- ★ Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano
- ★ Istituto Nazionale Tumori Regina Elena, Roma
- ★ Istituto Oncologico Veneto IRCCS-IOV, Padova
- ★ IRCCS Istituto Clinico Humanitas, Rozzano (Milano)
- ★ Istituto Tumori Giovanni Paolo II, Istituto di Ricovero e Cura a Carattere Scientifico, Bari
- ★ Istituto Nazionale Tumori IRCCS “Fondazione G.Pascale” (INT-Pascale), Napoli
- ★ IRCCS, Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture (Potenza)

- ★ Azienda Unità Sanitaria Locale di Reggio Emilia - IRCCS Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia
- ★ Istituto di Candiolo FPO-IRCCS, Candiolo (Torino)
- ★ IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella (Verona)
- Ospedale San Raffaele (OSR), Milano
- Fondazione IFOM - FIRC Institute of Molecular Oncology, Milano
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori [IRST]-IRCCS, Meldola (Forlì-Cesena)
- Fondazione Istituto Oncologico del Mediterraneo (IOM), Viagrande (Catania)
- IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano
- Istituto Dermatologico San Gallicano, Roma

Jordan

- King Hussein Cancer Center, Amman

Lithuania

- ★ National Cancer Institute, Vilnius

Norway

- ★ Oslo Universitetssykehus (OUS), Oslo

Poland

- Wielkopolskie Centrum Onkologii, Poznań

Portugal

- ★ Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO-Porto), Porto
- ★ Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa), Lisbon
- ★ Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO-Coimbra), Coimbra

Romania

- ★ The “Prof. Dr. Ion Chiricuta” Institute of Oncology (IOCN), Cluj-Napoca
- SC RTC Radiology Therapeutic Center – Amethyst Radiotherapy, Otopeni

Russia Federation

- Tatarstan Cancer Center “TCC”, Kazan
- N.N. Blokhin Russian Cancer Research Centre, Moscow
- National Medical Research Radiological Centre (NMRRC), Moscow

Serbia

- Oncology Institute of Vojvodina, Sremska Kamenica

Slovakia

- Biomedicinske centrum Slovenskej akadémie vied, Bratislava

Slovenia

- ★ Onkološki Inštitut Ljubljana, Ljubljana

Spain

- ★ Fundación Instituto Valenciano de Oncología IVO, Valencia
- Institut Català d'Oncologia ICO, L'Hospitalet de Llobregat (Barcelona)

Sweden

- ★ Karolinska Institute and University Hospital, Stockholm
- ★ Skånes Universitetssjukhus, Lund
- ★ Sahlgrenska University Hospital, Göteborg
- Uppsala University Hospital, Uppsala

Switzerland

- Comprehensive Cancer Center Zürich (CCCZ), Zürich

Tanzania

- The Aga Khan Hospital, Dar es Salaam, Dar es Salaam

The Netherlands

- ★ Netherlands Cancer Institute, Amsterdam

- ★ Maastricht University Medical Centre, Maastricht
- ★ University Medical Center Groningen Comprehensive Cancer Center (UMCG-CCC), Groningen
- Erasmus MC Cancer Institute, Rotterdam
- IKNL Integraal Kankercentrum Nederland, Utrecht
- Radboudumc Centrum voor Oncologie, Nijmegen
- Rijnstate, Arnhem

Turkey

- ★ Anadolu Saglik Merkezi, Kocaeli
- Dokuz Eylul Üniversitesi Onkoloji Enstitüsü, Izmir

Ukraine

- RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR), Kyiv

United Kingdom

- ★ The Christie NHS Foundation Trust, Manchester
- ★ Cambridge Cancer Centre, Cambridge
- ★ King's Health Partners Integrated Cancer Centre, London
- Imperial College Healthcare NHS Trust, London

Viet Nam

- Bệnh viện K Việt Nam National Cancer Hospital, Hanoi

The OECI Network

- ★ OECI Members A&D certified Comprehensive Cancer Centre
- ★ OECI Members A&D certified Cancer Centre
- ★ OECI Members in the A&D process
- Other OECI Members

